Tango Therapeutics' drug vopimetostat combined with daraxonrasib has shown a promising early signal in treating pancreatic cancer, based on a small group of 12 previously treated patients. A larger Phase 3 trial is planned to test the drug as a first-line treatment, but details on its design and regulatory approval are still uncertain. Additional studies in lung cancer and CNS cancers will reveal if the drug can succeed beyond this initial result. While the company has enough funding for now, key trials and potential market launch are still years away, making the stock a cautious hold for investors.
Over the past decade, an investment of $10,000 in AMD grew to more than $700,000, significantly outperforming the S&P 500, which turned the same amount into about $42,000. This highlights AMD's exceptional growth and strong market performance compare...
MDA Space successfully deployed the first eight satellites for Globalstar Inc.'s 2-R mission into low Earth orbit using a SpaceX Falcon 9 rocket. These satellites, developed and tested in Montréal, mark MDA Space's first prime contract for commercial...
Cornerstone Total Return Fund and Cornerstone Strategic Investment Fund have announced a rights offering allowing shareholders to buy new shares at a 4% premium to NAV. This move may temporarily reduce current market premiums and cause share dilution...
Daily Journal Corporation (DJCO) demonstrated solid revenue growth driven by increased sales of its journal technologies to government agencies, with some expenses being non-recurring. The company's marketable holdings have appreciated since June, bu...
Autonomous AI agents have completed over 2 million transactions on the XRP Ledger, but the total value moved is only about $7,400. These microtransactions, averaging just $0.0035 each, demonstrate the ledger's capability for high-frequency, low-cost ...
